Xing Wang

Also affiliated with Tianjin University of Technology, Guangxi University, Shenyang University of Technology, Donghua University, Shanghai Jiao Tong University, Shanghai University of Sport, Peking University, Sichuan University, Kunming Medical University, China Rehabilitation Research Center, Tianjin Medical University General Hospital, Wuhan University, West China Hospital of Sichuan University, Third People's Hospital of Chengdu, Peking University Cancer Hospital, Shenzhen Maternity and Child Healthcare Hospital, Zhongnan Hospital of Wuhan University, The Affiliated Yongchuan Hospital of Chongqing Medical University, Shanghai Children's Hospital, Southern Medical University, Lanzhou University, Chongqing Medical University, Dalian Polytechnic University, Tsinghua University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer”.